BMRN Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 24.92% compared to Biomarin Pharmaceutical's net margin of 19.72%. Biomarin Pharmaceutical's return on equity of 9.62% beat Gilead Sciences's return on equity of 32.29%.

Biomarin Pharmaceutical has a consensus price target of $96.02, signalling upside risk potential of 63.13%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 18.71%. Given that Biomarin Pharmaceutical has higher upside potential than Gilead Sciences, analysts believe Biomarin Pharmaceutical is more attractive than Gilead Sciences.

Biomarin Pharmaceutical has a beta of 0.268, which suggesting that the stock is 73.157% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.2% to investors and pays a quarterly dividend of $0.79 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.1M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Biomarin Pharmaceutical's net income of $185.7M is lower than Gilead Sciences's net income of $1.3B. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 21.88x while Gilead Sciences's PE ratio is 20.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.94x versus 4.25x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 24.92% compared to Biomarin Pharmaceutical's net margin of -907.48%. Biomarin Pharmaceutical's return on equity of 9.62% beat Moderna's return on equity of -29.23%.

Biomarin Pharmaceutical has a consensus price target of $96.02, signalling upside risk potential of 63.13%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 93.66%. Given that Moderna has higher upside potential than Biomarin Pharmaceutical, analysts believe Moderna is more attractive than Biomarin Pharmaceutical.

Biomarin Pharmaceutical has a beta of 0.268, which suggesting that the stock is 73.157% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.1M, which are larger than Moderna quarterly revenues of $107M. Biomarin Pharmaceutical's net income of $185.7M is higher than Moderna's net income of -$971M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 21.88x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.94x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 24.92% compared to Biomarin Pharmaceutical's net margin of -60.08%. Biomarin Pharmaceutical's return on equity of 9.62% beat Sarepta Therapeutics's return on equity of -20.94%.

Biomarin Pharmaceutical has a consensus price target of $96.02, signalling upside risk potential of 63.13%. On the other hand Sarepta Therapeutics has an analysts' consensus of $96.72 which suggests that it could grow by 166.66%. Given that Sarepta Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe Sarepta Therapeutics is more attractive than Biomarin Pharmaceutical.

Biomarin Pharmaceutical has a beta of 0.268, which suggesting that the stock is 73.157% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.365%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.1M, which are larger than Sarepta Therapeutics quarterly revenues of $744.9M. Biomarin Pharmaceutical's net income of $185.7M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 21.88x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.94x versus 1.80x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 24.92% compared to Biomarin Pharmaceutical's net margin of 23.33%. Biomarin Pharmaceutical's return on equity of 9.62% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Biomarin Pharmaceutical has a consensus price target of $96.02, signalling upside risk potential of 63.13%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 17.72%. Given that Biomarin Pharmaceutical has higher upside potential than Vertex Pharmaceuticals, analysts believe Biomarin Pharmaceutical is more attractive than Vertex Pharmaceuticals.

Biomarin Pharmaceutical has a beta of 0.268, which suggesting that the stock is 73.157% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $745.1M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Biomarin Pharmaceutical's net income of $185.7M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 21.88x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 3.94x versus 9.92x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.